MS Clinical Trials in Nevada
12 active trials · 4 recruiting
12 active multiple sclerosis clinical trials have at least one study site in Nevada, 4 of them currently recruiting participants. Trials are listed from ClinicalTrials.gov and cover disease-modifying therapies, symptom treatments, rehabilitation and imaging studies.
Eligibility, contact details and the exact site address are on each trial's ClinicalTrials.gov record, linked from every trial page. MS Buddy also lists 3 MS treatment centers in Nevada; many trial sites are run from those centers, and your neurologist is the best first person to ask about joining a study.
Active MS trials with sites in Nevada
RecruitingPhase 3
Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Teriflunomide
35 states1600 participantsDetails ›
Recruiting
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
Sponsor: TG Therapeutics, Inc.
No Intervention
29 states500 participantsDetails ›
RecruitingPhase 3
Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis
Sponsor: Sanofi
Frexalimab · Placebo
38 states900 participantsDetails ›
RecruitingPhase 4
Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
Sponsor: University of Colorado, Denver
Ozanimod
3 states100 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy and Safety of Fenebrutinib Compared With Ocrelizumab in Adult Participants With Primary Progressive Multiple Sclerosis
Sponsor: Hoffmann-La Roche
Fenebrutinib · Ocrelizumab
24 states985 participantsDetails ›
Closed to new patientsPhase 3
Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of a New Maintenance Dosing Regimen of Ofatumumab
Sponsor: Novartis Pharmaceuticals
Ofatumumab approved dose · Ofatumumab new dose
24 states196 participantsDetails ›
Closed to new patientsPhase 3
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
Sponsor: Novartis Pharmaceuticals
Ofatumumab · Tetanus toxoid (TT) containing vaccin…
32 states1882 participantsDetails ›
Closed to new patientsPhase 3
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
Sponsor: TG Therapeutics, Inc.
Ublituximab
14 states1100 participantsDetails ›
Closed to new patientsPhase 3
A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Ocrelizumab · Ocrelizumab
20 states864 participantsDetails ›
Closed to new patientsPhase 3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
Sponsor: Sanofi
Tolebrutinib · Placebo
27 states2500 participantsDetails ›
Closed to new patientsPhase 2
A Study to Investigate the Efficacy of Fenebrutinib in Relapsing Multiple Sclerosis (RMS)
Sponsor: Hoffmann-La Roche
Fenebrutinib · Placebo
2 states109 participantsDetails ›
Closed to new patientsPhase 4
Determining the Effectiveness of earLy Intensive Versus Escalation Approaches for RRMS
Sponsor: The Cleveland Clinic
Early Highly Effective Therapies Group · Escalation Therapies Group
8 states800 participantsDetails ›
MS trials in other states
The app
Check out the MS Buddy app
Track symptoms, monitor wellness, and stay on top of your MS care. It’s free, with no ads. Built by people living with MS.